EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide(1). Chemotherapies such as the topoisomerase II inhibitor (TopoIIi) etoposide effectively reduce disease in a minority of NSCLC patients(2,3); therefore, alternative drug targets, including epigenetic enzymes,...

Full description

Saved in:

Bibliographic Details
Published in:	Nature
Main Authors:	Fillmore, Christine M., Xu, Chunxiao, Desai, Pooja T., Berry, Joanne M., Rowbotham, Samuel P., Lin, Yi-Jang, Zhang, Haikuo, Marquez, Victor E., Hammerman, Peter S., Wong, Kwok-Kin, Kim, Carla F.
Format:	Artigo
Language:	Inglês
Published:	2015
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4393352/ https://ncbi.nlm.nih.gov/pubmed/25629630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14122
Tags:	Add Tag No Tags, Be the first to tag this record!

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors

Similar Items